Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.

From 2008-2013, the European indication for panitumumab required that patients' tumor KRAS exon 2 mutation status was known prior to starting treatment. To evaluate physician awareness of panitumumab prescribing information and how physicians prescribe panitumumab in patients with metastatic co...

Full description

Bibliographic Details
Main Authors:	Jörg Trojan, Laurent Mineur, Jiří Tomášek, Etienne Rouleau, Pavel Fabian, Giovanna de Maglio, Pilar García-Alfonso, Giuseppe Aprile, Aliki Taylor, George Kafatos, Gerald Downey, Jan-Henrik Terwey, J Han van Krieken
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4619650?pdf=render

Similar Items

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
by: Patel SB, et al.
Published: (2015-12-01)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Metastatic colorectal cancer: treatment with panitumumab
by: Antonio Silvinato, et al.

Treatment of metastatic colorectal cancer: focus on panitumumab
by: Tay RY, et al.
Published: (2015-06-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-02-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-01-01)

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan
by: Munenobu Kashiwa, et al.
Published: (2021-10-01)

Patient considerations in metastatic colorectal cancer – role of panitumumab
by: Rogers JE
Published: (2017-04-01)

Second-line panitumumab as a triweekly dose for patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer: a single-institution experience
by: Mohamed A. Daoud, et al.
Published: (2016-03-01)

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
by: Si-wei Zhou, et al.
Published: (2012-01-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
by: Adriana Camargo Carvalho, et al.
Published: (2017-01-01)

Panitumumab-induced acneiform rash in a patient with metastatic colon adenocarcinoma
by: Paulo Ricardo Saquete Martins-Filho, et al.
Published: (2013-01-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
by: Kimberly A. Lowe, et al.
Published: (2019-05-01)

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
by: Thaler Josef, et al.
Published: (2012-09-01)

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
by: Claus-Henning Köhne, et al.
Published: (2019-07-01)

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
by: Liu YG, et al.
Published: (2015-05-01)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
by: Francesca Battaglin, et al.
Published: (2018-01-01)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
by: Battaglin F, et al.
Published: (2019-06-01)

RESULTS OF PANITUMUMAB ADDITION TO CONVERSION THERAPY FOR COLORECTAL CANCER LIVER METASTASES
by: M. I. Sekacheva, et al.
Published: (2015-02-01)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
by: Ho Wai Derrick Siu, et al.
Published: (2021-08-01)

Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer
by: Mauro Moroni, et al.
Published: (2021-08-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
by: Hendrikx JJMA, et al.
Published: (2020-10-01)

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
by: Mareike Voigt, et al.
Published: (2012-11-01)

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
by: Howard Burris, et al.
Published: (2011-01-01)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer
by: Giampietro Gasparini, et al.
Published: (2014-09-01)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
by: Hiroya Taniguchi, et al.
Published: (2018-07-01)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
by: George P Kim, et al.
Published: (2008-06-01)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
by: Shigemasa Takamizawa, et al.
Published: (2021-02-01)

Beyond <it>KRAS</it> mutation status: influence of <it>KRAS</it> copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
by: Mekenkamp Leonie JM, et al.
Published: (2012-07-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Panitumumab v terapii metastaticheskogokolorektal'nogo raka: dannye klinicheskikhissledovaniy, problema kozhnoy toksichnosti
by: E V Artamonova
Published: (2010-09-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
by: Liao MZ, et al.
Published: (2020-12-01)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
by: E Allen Sickmier, et al.
Published: (2016-01-01)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
by: Yifan Xu, et al.
Published: (2018-11-01)